Skip to content
Companies

Emblok

Debris filter used during heart valve replacement

Raised to date

$6M

of $12M offered across 1 Form D filing

Still open
$6M
Investors
1
Last filed
Jun 18, 2026

About

Emblok, Inc. is a privately held Tampa, Florida medical device company developing the Emblok Embolic Protection System, a 360-degree whole-body embolic protection device used during transcatheter aortic valve replacement (TAVR). The device is delivered through femoral access, deployed across the aortic arch near the brachiocephalic artery, and captures calcium and tissue debris dislodged during valve replacement before it can reach the brain, kidneys, or visceral arteries. The company was formerly known as Innovative Cardiovascular Solutions. The system is investigational and its clinical use is limited to an FDA-approved study; a US multicenter randomized trial enrolling up to 532 TAVR patients is underway, having passed 50 patients enrolled in October 2024.

Where most cerebral embolic protection devices filter only the vessels feeding the brain, Emblok is designed as whole-body protection, capturing debris across all major arteries to also address acute kidney injury and peripheral vascular complications from TAVR.

Funding

  • EquityFiled Jun 18, 2026Form D
    $6M/ $12M

Product

Emblok Embolic Protection System (EPS)

Interventional cardiology device

A catheter-delivered 360-degree whole-body embolic protection filter deployed in the aortic arch during TAVR, which captures embolic debris while maintaining blood flow and is then re-sheathed and withdrawn via femoral access.

  • 360-degree whole-body coverage rather than cerebral-only filtration
  • Single femoral access delivery, deployment, capture, and retrieval workflow
  • Filter seats against vessel walls for full coverage while preserving blood flow

Built for

Interventional cardiologists, structural heart programs, and cardiac surgery centers performing TAVR on patients with aortic valve stenosis

People on file